References
- [cited 2017 Mar 17]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
- [cited 2017 Mar 17]. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm?s_cid=rr6207a1_w#PersonsAtRiskMedicalComplicationsAttributableSevereInfluenza.
- [cited 2017 Sep 28]. Available from: https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm123694.pdf
- Pellegrino P, Perrotta C, Clementi E, et al. Vaccine-drug interactions: cytokines, cytochromes, and molecular mechanisms. Drug Saf. 2015;38:781–787.
- Pellegrino P, Carnovale C, Borsadoli C, et al. Two cases of hallucination in elderly patients due to a probable interaction between flu immunization and tramadol. Eur J Clin Pharmacol. 2013;69:1615–1616.
- Pellegrino P, Clementi E, Capuano A, et al. Can vaccines interact with drug metabolism? Pharmacol Res. 2015;92:13–17.
- Pellegrino P, Carnovale C, Perrone V, et al. On the possible interaction between vaccines and drugs. Eur J Clin Pharmacol. 2014;70:369–371.
- Paliani U, Filippucci E, Gresele P. Significant potentiation of anticoagulation by flu-vaccine during the season 2001–2002. Haematologica. 2003;88:599–600.
- Weibert RT, Lorentz SM, Norcross WA, et al. Effect of influenza vaccine in patients receiving long-term warfarin therapy. Clin Pharm. 1986;5:499–503.
- Carroll DN, Carroll DG. Fatal intracranial bleed potentially due to a warfarin and influenza vaccine interaction. Ann Pharmacother. 2009;43:754–760.
- Bussey HI, Saklad JJ. Effect of influenza vaccine on chronic warfarin therapy. Drug Intell Clin Pharm. 1988;22:198–201.
- Raman KS, Chandrasekar T, Reeve RS, et al. Influenza vaccine induced rhabdomyolysis leading to acute renal transplant dysfunction. Nephrol Dial Transplant. 2006;21:530–531.
- Hamarat H, Yorulmaz G, Gönüllü EÖ, et al. Rhabdomyolysis probably induced by influenza vaccine and fibrate therapy. Eur J Rheumatol. 2015;2:169.
- Plotkin E, Bernheim J, Ben-Chetrit S, et al. Influenza vaccine–a possible trigger of rhabdomyolysis induced acute renal failure due to the combined use of cerivastatin and bezafibrate. Nephrol Dial Transplant. 2000;15:740–741.
- Shah SV, Reddy K. Rhabdomyolysis with acute renal failure triggered by the seasonal flu vaccination in a patient taking simvastatin. BMJ Case Rep. 2010; pii: bcr1120092485. doi:10.1136/bcr.11.2009.2485
- Callado RB, Carneiro TG, Parahyba CC, et al. Rhabdomyolysis secondary to influenza A H1N1 vaccine resulting in acute kidney injury. Travel Med Infect Dis. 2013;11(2):130–133.
- Robertson WC. Carbamazepine toxicity after influenza vaccination. Pediatr Neurol. 2002;26(1):61–63.
- Meredith CG, Christian CD, Johnson RF, et al. Schenker effects of influenza virus vaccine on hepatic drug metabolism. Clin Pharmacol Ther. 1985;396–401.
- Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. Clin Pharm. 1986;5(10):817–820.
- Levine M, Jones MW, Gribble M. Increased serum phenytoin concentration following influenza vaccination. Clin Pharm. 1984;3(5):505–509.
- Sawchuk RJ, Rector TS, Fordice JJ, et al. Effect of influenza vaccination on plasma phenytoin concentrations. Ther Drug Monit. 1979;1(2):285–288.
- Jackson ML, Nelson JC, Chen RT, et al. Vaccines and changes in coagulation parameters in adults on chronic warfarin therapy: a cohort study. Pharmacoepidemiol Drug Saf. 2007;790–796.
- Iorio AM, Camilloni B, Basileo M, et al. Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine. 2006;24(44–46):6624–6628.
- Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. Blood Coagul Fibrinolysis. 2002;13:297–300.
- Arnold WS, Mehta MK, Roberts JS. Influenza vaccine and anticoagulation control in patients receiving warfarin. Br J Clin Pract. 1990;44:136–139.
- Raj G, Kumar R, McKinney WP. Safety of intramuscular influenza immunization among patients receiving long-term warfarin anticoagulation therapy. Arch Intern Med. 1995;155:1529–1531.
- MacCallum P, Madhani M, Mt-Isa S, et al. Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. Pharmacoepidemiol Drug Saf. 2007;16:786–789.
- Woodcock J, Behrman RE, Dal Pan GJ. Role of postmarketing surveillance in contemporary medicine. Annu Rev Med. 2011;62:1–10.
- [cited 2017 Mar 17]. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.ShowDrugInteractionsResults
- Centers for Disease Control and Prevention. Vaccine adverse event reporting system – United States. MMWR Morb Mortal Wkly Rep. 1990;39:730–733.
- Shimabukuro TT, Nguyen M, Martin D, et al. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–4405.
- [cited 2017 Mar 17]. Available from: http://www.who.int/vaccine_safety/publications/aevi_manual.pdf
- Singleton JA, Lloyd JC, Mootrey GT, et al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. Vaccine. 1999;17:2908–2917.
- Food, Drug Administration, 21CFR Part 600.80. Postmarketing reporting of adverse experiences. Fed Reg. 1997;62:52252–52253.
- Medical dictionary for regulatory activities. [cited 2017 Mar 17]. Available from: http://www.meddramsso.com.
- Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42:409–419.
- Lindquist M, Edwards IR. The WHO programme for international drug monitoring, its database, and the technical support of the Uppsala monitoring center. J Rheumatol. 2001;28:1180–1187.
- Norvegian Institute of Public Health. Guidelines for ATC classification and DDD assignment 2011. Oslo (Norway): WHO Collaborating Centre for Drug Statistics Methodology; 2010.
- [cited 2017 Mar 17]. Available from: https://www.meddra.org/standardised-meddra-queries
- [cited 2017 Mar 17]. Available from: http://www.rch.org.au/clinicalguide/guideline_index/Anticonvulsant_Poisoning/
- Spiller HA, Bosse GM. Management of acute anticonvulsant overdose. CNS Drugs. 1996;6:113.
- [cited 2017 Mar 17]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/tegretol.pdf
- [cited 2017 Mar 17]. Available from: http://www.who.int/vaccine_safety/publications/aevi_manual.pdf
- Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674–680.
- Bernstein ED, Gardner EM, Abrutyn E, et al. Cytokine production after influenza vaccination in a healthy elderly population. Vaccine. 1998;16:1722–1731.
- Gorski JC, Hall SD, Becker P, et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther. 2000;67:32–43.
- Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol. 1993;44:707–715.
- Abdel-Razzak Z, Corcos L, Fautrel A, et al. Transforming growth factor-beta 1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol. 1994;46:1100–1110.
- Clark MA, Bing BA, Gottschall PE, et al. Differential effect of cytokines on the phenobarbital or 3-methylcholanthrene induction of P450 mediated monooxygenase activity in cultured rat hepatocytes. Biochem Pharmacol. 1995;49:97–104.
- Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol. 2005;1:629–640.
- Hayney MS, Muller D. Effect of influenza immunization on CYP3A4 activity in vivo. J Clin Pharmacol. 2003;43(12):1377–1381.
- Palache A, Oriol-Mathieu V, Fino M, et al. Influenza Vaccine Supply task force (IFPMA IVS). Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): little progress in estimated global vaccination coverage. Vaccine. 2015;33:5598–5605.
- Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003;3:91–95.
- Sarco DP, Bourgeois BF. The safety and tolerability of newer antiepileptic drugs in children and adolescents. CNS Drugs. 2010;24:399–430.
- World Health Organization. Mental health [online]. [cited 2017 Sep 28. Available from: http://www.who.int/mental_health/neurology/epilepsy/en/
- Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand. 2006;113:405–411.
- Maricich SM, Neul JL, Lotze TE, et al. Neurologic complications associated with influenza A in children during the 2003-2004 influenza season in. Pediatrics. 2004;114:626–633.
- Franco V, Crema F, Iudice A, et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res. 2013;70:35–40.
- [cited 2017 Sep 28]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/635921/Inactivated_influenza_vaccine_information_for_healthcare_practitioners.pdf. .
- Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in thecytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleedingcomplications. Lancet. 1999;353:717–719.
- Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med. 2006;119:400–409.
- Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009;80:832–838.
- Joshi HN. Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity. Pharm Pharmacol Commun. 1999;5:269–271.
- Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–1690.
- Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007;19:67–73.
- Backes JM, Howard PA, Ruisinger JF, et al. Does simvastatin cause more myotoxicity compared with other statins? Ann Pharmacother. 2009;43:2012–2020.
- Le Vee M, Jouan E, Moreau A, et al. Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes. Fundam Clin Pharmacol. 2011;25:99–103.
- Le Vee M. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos. 2009;37:685–693.
- Lopez-Ramirez MA, Kingsley Male D, Wang C, et al. Cytokine-induced changes in the gene expression profile of a human cerebral microvascular endothelial cell-line, hCMEC/D3. Fluids and Barriers of the CNS. 2013;10:27.
- Grube M, Köck K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006;80(6):607–620.
- Romaine SPR, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 2010;10:1–11.
- Lindsley CW. The top prescription drugs of 2011 in the United States: antipsychotics and antidepressants once again lead CNS therapeutics. ACS Chem Neurosci. 2012;3:630–631.
- Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32–43.
- Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann. 2004;33:599–606.
- Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1,2009–january 31, 2010. Vaccine. 2010;28:7248–7255.